|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hu Y and Fu L: Targeting cancer stem
cells: A new therapy to cure cancer patients. Am J Cancer Res.
2:340–356. 2012.PubMed/NCBI
|
|
3
|
Gilbert CA and Ross AH: Cancer stem cells:
Cell culture, markers, and targets for new therapies. J Cell
Biochem. 108:1031–1038. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chambers I, Silva J, Colby D, Nichols J,
Nijmeijer B, Robertson M, Vrana J, Jones K, Grotewold L and Smith
A: Nanog safeguards pluripotency and mediates germline development.
Nature. 450:1230–1234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zbinden M, Duquet A, Lorente-Trigos A,
Ngwabyt SN, Borges I and Ruiz i Altaba A: NANOG regulates glioma
stem cells and is essential in vivo acting in a cross-functional
network with GLI1 and p53. EMBO J. 29:2659–2674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Freberg CT, Dahl JA, Timoskainen S and
Collas P: Epigenetic reprogramming of OCT4 and NANOG regulatory
regions by embryonal carcinoma cell extract. Mol Biol Cell.
18:1543–1553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gu G, Yuan J, Wills M and Kasper S:
Prostate cancer cells with stem cell characteristics reconstitute
the original human tumor in vivo. Cancer Res. 67:4807–4815. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jeter CR, Liu B, Liu X, Chen X, Liu C,
Calhoun-Davis T, Repass J, Zaehres H, Shen JJ and Tang DG: NANOG
promotes cancer stem cell characteristics and prostate cancer
resistance to androgen deprivation. Oncogene. 30:3833–3845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding Y, Yu AQ, Li CL, Fang J, Zeng Y and
Li DS: TALEN-mediated Nanog disruption results in less
invasiveness, more chemosensitivity and reversal of EMT in Hela
cells. Oncotarget. 5:8393–8401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Djurovic S, Iversen N, Jeansson S, Hoover
F and Christensen G: Comparison of nonviral transfection and
adeno-associated viral transduction on cardiomyocytes. Mol
Biotechnol. 28:21–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoshijima M, Ikeda Y, Iwanaga Y,
Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, et
al: Chronic suppression of heart-failure progression by a
pseudophosphorylated mutant of phospholamban via in vivo cardiac
rAAV gene delivery. Nat Med. 8:864–871. 2002.PubMed/NCBI
|
|
13
|
Zangi L, Lui KO, von Gise A, Ma Q, Ebina
W, Ptaszek LM, Später D, Xu H, Tabebordbar M, Gorbatov R, et al:
Modified mRNA directs the fate of heart progenitor cells and
induces vascular regeneration after myocardial infarction. Nat
Biotechnol. 31:898–907. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li B, Xu L, Lu WY, Xu W, Wang MH, Yang K,
Dong J, Ding XY and Huang YH: A whole-mechanical method to
establish human embryonic stem cell line HN4 from discarded
embryos. Cytotechnology. 62:509–518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Landry JJ, Pyl PT, Rausch T, Zichner T,
Tekkedil MM, Stütz AM, Jauch A, Aiyar RS, Pau G, Delhomme N, et al:
The genomic and transcriptomic landscape of a HeLa cell line. G3
(Bethesda). 3:1213–1224. 2013. View Article : Google Scholar
|
|
16
|
Pérez-Tomás R: Multidrug resistance:
Retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goda K, Bacsó Z and Szabó G: Multidrug
resistance through the spectacle of P-glycoprotein. Curr Cancer
Drug Targets. 9:281–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Casas E, Kim J, Bendesky A, Ohno-Machado
L, Wolfe CJ and Yang J: Snail2 is an essential mediator of
Twist1-induced epithelial mesenchymal transition and metastasis.
Cancer Res. 71:245–254. 2011. View Article : Google Scholar : PubMed/NCBI
|
